PMV Pharmaceuticals (PMVP) Current Assets (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Current Assets came in at $95.8 million in Q1 2026, down 41.42% YoY from $163.5 million in Q1 2025, and down 16.88% on a QoQ basis from $115.2 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Current Assets (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Current Assets data on file, last reported at $95.8 million in Q1 2026.
- Quarterly Current Assets fell 41.42% year-over-year to $95.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.8 million (down 41.42% YoY) and the FY2025 annual result came in at $115.2 million, down 34.4% from the prior year.
- Current Assets retreated to $95.8 million in Q1 2026, from $115.2 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $288.0 million in Q1 2022 to a low of $95.8 million in Q1 2026.
- A 5-year average of $197.5 million and a median of $202.5 million in 2024 frame the typical range for Current Assets.
- Annual changes were most pronounced in 2024 — Current Assets grew 14.9% — and 2026, when it tumbled 41.42%.
- Tracing PMVP's Current Assets over 5 years: stood at $247.0 million in 2022, then retreated by 16.03% to $207.4 million in 2023, then fell by 15.31% to $175.7 million in 2024, then sank by 34.4% to $115.2 million in 2025, then dropped by 16.88% to $95.8 million in 2026.
- The last three Current Assets figures came in at $95.8 million (Q1 2026), $115.2 million (Q4 2025), and $132.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 1.76 Bn |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 81.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 95.78 Mn |
| Dec 31, 2025 | 115.23 Mn |
| Sep 30, 2025 | 132.45 Mn |
| Jun 30, 2025 | 145.31 Mn |
| Mar 31, 2025 | 163.50 Mn |
| Dec 31, 2024 | 175.66 Mn |
| Sep 30, 2024 | 189.62 Mn |
| Jun 30, 2024 | 218.79 Mn |
| Mar 31, 2024 | 202.46 Mn |
| Dec 31, 2023 | 207.41 Mn |
| Sep 30, 2023 | 205.30 Mn |
| Jun 30, 2023 | 190.41 Mn |
| Mar 31, 2023 | 233.28 Mn |
| Dec 31, 2022 | 247.01 Mn |
| Sep 30, 2022 | 265.18 Mn |
| Jun 30, 2022 | 281.87 Mn |
| Mar 31, 2022 | 288.04 Mn |
| Dec 31, 2021 | 301.29 Mn |
| Sep 30, 2021 | 313.56 Mn |
| Jun 30, 2021 | 323.08 Mn |